KR101521861B1 - Alk 억제제의 사용 방법 - Google Patents

Alk 억제제의 사용 방법 Download PDF

Info

Publication number
KR101521861B1
KR101521861B1 KR1020137023001A KR20137023001A KR101521861B1 KR 101521861 B1 KR101521861 B1 KR 101521861B1 KR 1020137023001 A KR1020137023001 A KR 1020137023001A KR 20137023001 A KR20137023001 A KR 20137023001A KR 101521861 B1 KR101521861 B1 KR 101521861B1
Authority
KR
South Korea
Prior art keywords
alk
delete delete
compound
eml4
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137023001A
Other languages
English (en)
Korean (ko)
Other versions
KR20130121174A (ko
Inventor
난신 리
제니퍼 엘. 하리스
피터 맥나마라
팡시안 선
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101521861(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20130121174A publication Critical patent/KR20130121174A/ko
Application granted granted Critical
Publication of KR101521861B1 publication Critical patent/KR101521861B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137023001A 2011-02-02 2012-02-02 Alk 억제제의 사용 방법 Active KR101521861B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
US61/438,878 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (2)

Publication Number Publication Date
KR20130121174A KR20130121174A (ko) 2013-11-05
KR101521861B1 true KR101521861B1 (ko) 2015-05-21

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137023001A Active KR101521861B1 (ko) 2011-02-02 2012-02-02 Alk 억제제의 사용 방법

Country Status (22)

Country Link
US (1) US8703787B2 (cg-RX-API-DMAC10.html)
EP (1) EP2670401B1 (cg-RX-API-DMAC10.html)
JP (1) JP5837095B2 (cg-RX-API-DMAC10.html)
KR (1) KR101521861B1 (cg-RX-API-DMAC10.html)
CN (1) CN103458881B (cg-RX-API-DMAC10.html)
AU (1) AU2012212142B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013019643B1 (cg-RX-API-DMAC10.html)
CA (1) CA2824092C (cg-RX-API-DMAC10.html)
CY (1) CY1116662T1 (cg-RX-API-DMAC10.html)
DK (1) DK2670401T3 (cg-RX-API-DMAC10.html)
EA (1) EA023404B1 (cg-RX-API-DMAC10.html)
ES (1) ES2543567T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20150946T1 (cg-RX-API-DMAC10.html)
HU (1) HUE025395T2 (cg-RX-API-DMAC10.html)
ME (1) ME02200B (cg-RX-API-DMAC10.html)
MX (1) MX2013008791A (cg-RX-API-DMAC10.html)
PL (1) PL2670401T3 (cg-RX-API-DMAC10.html)
PT (1) PT2670401E (cg-RX-API-DMAC10.html)
RS (1) RS54189B1 (cg-RX-API-DMAC10.html)
SI (1) SI2670401T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201500300B (cg-RX-API-DMAC10.html)
WO (1) WO2012106540A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
AU2013341271A1 (en) * 2012-11-07 2015-05-14 Novartis Ag Combination therapy
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
JP6510510B2 (ja) * 2013-07-11 2019-05-08 ベータ ファーマシューティカルズ カンパニー リミテッド プロテインチロシンキナーゼモジュレーター及び使用方法
US20160361314A1 (en) * 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
US10053458B2 (en) * 2014-06-17 2018-08-21 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
CN106220644B (zh) 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技(苏州)有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
SG11201901251SA (en) * 2016-08-29 2019-03-28 Univ Michigan Regents Aminopyrimidines as alk inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
ATE542801T1 (de) * 2003-08-15 2012-02-15 Novartis Ag Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
WO2008007368A2 (en) 2006-07-10 2008-01-17 Rf Dynamics Ltd. Food preparation
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233964B2 (en) * 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Neoplasia. Vol.13(1), pp.1-11 *
Neoplasia. Vol.13(1), pp.1-11*

Also Published As

Publication number Publication date
EA201391114A1 (ru) 2013-12-30
CA2824092C (en) 2020-06-30
AU2012212142A1 (en) 2013-08-15
ME02200B (me) 2016-02-20
JP2014504646A (ja) 2014-02-24
CA2824092A1 (en) 2012-08-09
DK2670401T3 (en) 2015-09-07
EP2670401B1 (en) 2015-06-10
KR20130121174A (ko) 2013-11-05
JP5837095B2 (ja) 2015-12-24
HUE025395T2 (en) 2016-02-29
US20130296357A1 (en) 2013-11-07
CN103458881B (zh) 2015-08-12
BR112013019643B1 (pt) 2022-04-19
CN103458881A (zh) 2013-12-18
WO2012106540A1 (en) 2012-08-09
AU2012212142B2 (en) 2015-09-24
RS54189B1 (sr) 2015-12-31
SMT201500300B (it) 2016-01-08
PT2670401E (pt) 2015-10-12
BR112013019643A2 (pt) 2016-10-04
PL2670401T3 (pl) 2015-11-30
SI2670401T1 (sl) 2015-10-30
HRP20150946T1 (hr) 2015-10-09
MX2013008791A (es) 2013-10-07
EA023404B1 (ru) 2016-05-31
CY1116662T1 (el) 2017-03-15
US8703787B2 (en) 2014-04-22
EP2670401A1 (en) 2013-12-11
ES2543567T3 (es) 2015-08-20

Similar Documents

Publication Publication Date Title
JP5837095B2 (ja) Alk阻害剤の使用方法
JP5852173B2 (ja) チロシンキナーゼ活性阻害作用を有する新規な縮合ピリミジン誘導体
CN101137382B (zh) 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
TWI617556B (zh) 經炔基取代之喹唑啉化合物及其使用方法
JP2021501145A (ja) 血液学的障害を治療するための化合物および組成物
US12414945B2 (en) Therapeutic agent for breast cancer
CN107949387A (zh) 用谷氨酰胺酶抑制剂治疗肺癌
KR20230154793A (ko) 암 치료를 위한 병용 요법
JP2019511554A (ja) 静止細胞標的化およびegfr阻害剤を用いた新生物の処置のための組み合わせ
KR20250069693A (ko) 암 치료
KR20210038906A (ko) 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
TW201806600A (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
CA3196283A1 (en) Csf1r kinase inhibitor and use thereof
KR20230152652A (ko) 암 치료를 위한 병용 요법
KR20210126654A (ko) 암 치료
JP2024514098A (ja) ErbB2突然変異体を標的とする阻害薬の調製における化合物の使用
EP3012248B1 (en) Substance having tyrosine kinase inhibitory activity and preparation method and use thereof
CN117098537A (zh) 用于癌症治疗的联合疗法
TW202140005A (zh) 用於治療發炎疾病之新穎藥物
CN103705517A (zh) Src激酶抑制剂对溶骨性病变的抑制
WO2016052081A1 (ja) 癌細胞増殖抑制剤、抗癌剤、及びこれらのスクリーニング方法、並びに新規化合物

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20180427

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190429

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 12